Market Access News | pharmaphorum

News

UK pharma has concerns about the new NHS 10-year plan

The ABPI is worried about investment in medicines and moves that could limit patient and doctor treatment choice in the NHS 10-year plan.

News

AZ claims EU okay for Imfinzi in bladder cancer

AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.

News

Choose Europe for Life Sciences campaign image

Pharma welcomes EU push to restore life sciences sector

European pharma trade group EFPIA has said that a strategy launched by the EU to bolster the region's standing in life sciences is a "step forward."

News

NICE relents on Takeda colorectal cancer drug Fruzaqla

Colorectal cancer patients could soon have access via the NHS to a targeted oral drug that can give them more precious time with their loved ones.

News

The NHS 10 Year Plan arrives – what are the highlights?

After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new 10-year plan for the NHS.

News

Dizal set to bring lung cancer drug Zegfrovy to US

Dizal gets US approval for an oral therapy for EGFR exon 20-mutated NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant.

UK pharma has concerns about the new NHS 10-year plan

AZ claims EU okay for Imfinzi in bladder cancer

Pharma welcomes EU push to restore life sciences sector

NICE relents on Takeda colorectal cancer drug Fruzaqla

The NHS 10 Year Plan arrives – what are the highlights?

Dizal set to bring lung cancer drug Zegfrovy to US

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks